Compare American Electric Power Company Inc (AEP) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Electric Power Company Inc vs Incyte Corporation — how do they compare? American Electric Power Company Inc trades at $123.63 (market cap $67.28B), while Incyte Corporation trades at $120.45 (market cap $24.54B). The key difference: American Electric Power Company Inc is far larger — about 2.7× Incyte Corporation's market cap, and American Electric Power Company Inc pays a 3.07% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| AEP | INCY | |
|---|---|---|
Market Cap | $67.28B | $24.54B |
Sector | Utilities | Health |
52-Week High | $138.69 | $129.93 |
52-Week Low | $106.44 | $81.61 |
Enterprise Value | $120.17B | $20.04B |
Dividend Yield | 3.07% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American Electric Power Company Inc
American Electric Power is one of the largest regulated utilities in the United States, providing electricity generation, transmission, and distribution to more than 5 million customers in 11 states. About 43% of AEP's of capacity is coal, with the remainder from a mix of natural gas (27%), renewable energy and hydro (19%), nuclear (7%), and demand response (4%). Vertically integrated utilities, transmission and distribution, and generation and marketing support earnings.
Read more on AEP →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
